



# PHILIPPINE RHEUMATOLOGY ASSOCIATION

**A Subspecialty Society of the Philippine College of Physicians  
A Specialty Division of the Philippine Medical Association**

Room 1408 North Tower, Cathedral Heights Building Complex  
St. Luke's Medical Center, E. Rodriguez Sr. Avenue, Quezon City 1102 Philippines  
Tel No. (632) 723-0101 loc 5148 | Tel/ Fax No. (632) 726-8875  
Email: [philtrheuma@gmail.com](mailto:philtrheuma@gmail.com) | Web: [www.rheumatology.org.ph](http://www.rheumatology.org.ph)

## CALL FOR ABSTRACTS

For those with completed research papers, you may submit your abstracts to the PRA Research Committee through the PRA secretariat (email: [philtrheuma@gmail.com](mailto:philtrheuma@gmail.com)). The mechanics are as follows:

1. The content of the paper must focus on a rheumatology topic.
2. Abstracts should not exceed 325 words.
3. This submission should be the first to the Philippine Rheumatology Association.
4. Use standard abbreviations (spell out in full at first mention, add abbreviations in parenthesis). Use numerals for numbers.
5. Organize the body of abstract using headings and information described in the sample provided below.
6. The abstract must be submitted as two files- one file with all the information as requested below and the second file without the name of author, presenter, institution and telephone numbers.

---

### SAMPLE SUBMISSION

Name of Author/s: \_\_\_\_\_  
Name of Presenter: \_\_\_\_\_  
Institution: \_\_\_\_\_  
Tel. No.: \_\_\_\_\_ Fax No.: \_\_\_\_\_

### CAPITALIZE ENTIRE ABSTRACT TITLE.

**OBJECTIVES:** State main question or study objective(s) or hypothesis.

### METHODS

**DESIGN:** Describe study design and temporal direction (retrospective or prospective). For trials, indicated if randomized or blinded.

**SETTING:** Indicate the study setting (hospital, clinic, and community). Also include the level of clinical care (primary or tertiary) (private practice or institutional).

**PATIENTS/PARTICIPANTS:** State selection procedures, entry criteria and numbers of participants entering and finishing the study.

---



# PHILIPPINE RHEUMATOLOGY ASSOCIATION

**A Subspecialty Society of the Philippine College of Physicians  
A Specialty Division of the Philippine Medical Association**

Room 1408 North Tower, Cathedral Heights Building Complex  
St. Luke's Medical Center, E. Rodriguez Sr. Avenue, Quezon City 1102 Philippines  
Tel No. (632) 723-0101 loc 5148 | Tel/ Fax No. (632) 726-8875  
Email: [philrheuma@gmail.com](mailto:philrheuma@gmail.com) | Web: [www.rheumatology.org.ph](http://www.rheumatology.org.ph)

**INTERVENTIONS IF ANY:** Describe the essential features of any interventions/exposure, including their method and duration of administration.

**MAIN OUTCOME MEASURE(S):** The primary study outcome measures should be indicated as planned before the data collection began.

**ANALYSIS:** The statistical analysis as planned in the study.

**ETHICAL CONSIDERATIONS:** This includes technical and ethics approval, informed consent, confidentiality, and other concerns.

**RESULTS:** Describe measurements that are not evident from the nature of the main results and indicate any blinding. If possible, the results should be accompanied by confidence intervals (most often the 95% interval) and the exact level of statistical significance. For comparative studies, confidence intervals should relate to the differences between groups. Absolute values should be indicated when risk changes or effect sizes are given.

**CONCLUSION:** State only those conclusions of the study that are directly supported by data, along with their clinical application (avoiding generalization) or whether additional study is required before the information could be used in usual clinical settings.

**RESEARCH FUNDING:** ex PCHRD, WHO, etc.

---

**DEADLINE** for submission of abstracts is on **31 March 2022**

**IMPORTANT:** Papers accepted for presentation in the free communication sessions must be presented as scheduled. Presenters who for justifiable reasons are unable to present, **MUST** formally withdraw in writing to the Scientific Committee. Likewise, those who had received a research grant through the PRA Research Committee may take this opportunity to present their completed papers as part of the grant requirements.